hepatocellular-carcinoma
(4)
Eureka Therapeutics, Inc.
Eureka Therapeutics is a clinical-stage biopharmaceutical company in Emeryville, California, developing next-generation T-cell therapies for cancer, with a focus on hard-to-treat solid tumors. Founded in 2006 by Dr. Cheng Liu, the company pairs its E-ALPHA phage-display antibody engine with its ARTEMIS T-cell receptor platform - an alternative to conventional CAR-T designed to keep engineered T cells potent inside immunosuppressive tumors while sharply reducing the inflammatory cytokine release linked to CAR-T toxicity. Its lead program, ECT204, targets GPC3-positive advanced liver cancer and has received FDA RMAT designation.
Auransa
Auransa is a clinical-stage, AI-native biopharmaceutical company in Palo Alto, California, that uses a proprietary machine-learning platform - the SMarTR Engine - to mine large, heterogeneous human disease datasets and discover novel cancer therapies without starting from a predefined drug target. Founded in 2014 by Pek Lum and Viwat Visuthikraisee, the company pairs each predicted compound with the patient subtypes most likely to respond, aiming to improve the odds of clinical success. Its lead program, AU-409, an RNA transcription modulator for advanced liver cancer, is in Phase 1 trials, with additional programs including heart-safe chemotherapy.
Autem Therapeutics
Autem Therapeutics is a Hanover, New Hampshire bioelectric oncology company developing AutEMsys, a non-invasive, non-toxic device that delivers personalized, low-level, amplitude-modulated electromagnetic frequencies to patients with solid tumors. Founded by medical oncologist Frederico Costa and led by CEO Michael Choukas, the company targets hepatocellular carcinoma (liver cancer) and other hard-to-treat cancers, aiming to make effective cancer care portable, affordable, and accessible worldwide. Its lead program has earned FDA Breakthrough Device designation for advanced HCC.
Geneos Therapeutics
Geneos Therapeutics is a clinical-stage biotherapeutics company in Plymouth Meeting / Philadelphia, Pennsylvania, building DNA-based personalized immunotherapies for cancer. Its proprietary GT-EPIC platform reads a patient's own tumor mutations and manufactures a custom DNA plasmid vaccine encoding up to 40 of that patient's unique neoantigens, delivered intradermally with an IL-12 cytokine adjuvant and electroporation. In 2024 the company published Phase 1/2 GT-30 data in Nature Medicine showing its vaccine plus pembrolizumab generated new neoantigen-specific T cells and clinical responses in advanced liver cancer - billed as the first definitive demonstration of a personalized cancer vaccine boosting response to anti-PD-1 therapy.